Journal
ACTA OPHTHALMOLOGICA
Volume 86, Issue 7, Pages 716-726Publisher
WILEY
DOI: 10.1111/j.1755-3768.2008.01250.x
Keywords
antiglaucoma medications; benzalkonium chloride; glaucoma; preservatives
Categories
Funding
- Alcon
- Alcon, Inc.
- Allergan, Inc.
- Pfizer, Inc.
- Santen Oy
- Laboratoires Thea SA
Ask authors/readers for more resources
Antiglaucoma medications are often associated with ocular adverse reactions such as dry eye, and burning or stinging sensations. These undesirable effects may lead to treatment discontinuation and reduced quality of life in patients with glaucoma. Antiglaucoma medications usually contain benzalkonium chloride (BAK) as a preservative. Animal studies, in vitro studies and in vivo experiments have demonstrated various adverse effects of BAK. Clinical studies have also shown an increased incidence of adverse events with BAK and have demonstrated that the withdrawal of preservatives reduces these effects. Collectively, these data suggest that preservative-free antiglaucoma treatments have clinically relevant benefits for patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available